CLINICAL_TRIALS
trial_result
· 2022-05-16
Clinical Trial Update: Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma [Phase 3]
Summary
Phase 3 trial update for pembrolizumab with talimogene laherparepvec vs placebo in unresectable melanoma has been terminated with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Amgen | Conditions: Melanoma | Phase 3 | Status: TERMINATED | Results posted: 2022-05-16